Zymeworks Inc. (ZYME)
Largest Insider Buys in Sector
ZYME Stock Price History Chart
ZYME Stock Performance
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Insider Activity of Zymeworks Inc.
Over the last 12 months, insiders at Zymeworks Inc. have bought $0 and sold $436,288 worth of Zymeworks Inc. stock.
On average, over the past 5 years, insiders at Zymeworks Inc. have bought $16.77M and sold $3.09M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,350,000 shares for transaction amount of $27.2M was made by EcoR1 Capital, LLC (10 percent owner) on 2023‑06‑16.
List of Insider Buy and Sell Transactions, Zymeworks Inc.
| 2024-01-08 | Sale | Galbraith Kenneth | Chair & CEO | 5,706 0.0079% | $11.22 | $63,996 | -16.26% | |
| 2024-01-08 | Sale | Moore Paul Andrew | Chief Scientific Officer | 2,339 0.0033% | $11.22 | $26,233 | -16.26% | |
| 2024-01-08 | Sale | Astle Christopher | SVP & Chief Financial Officer | 1,431 0.002% | $11.22 | $16,050 | -16.26% | |
| 2024-01-05 | Sale | Galbraith Kenneth | Chair & CEO | 18,198 0.0262% | $10.65 | $193,849 | -8.70% | |
| 2024-01-05 | Sale | Moore Paul Andrew | Chief Scientific Officer | 7,460 0.0107% | $10.65 | $79,465 | -8.70% | |
| 2024-01-05 | Sale | Astle Christopher | SVP & Chief Financial Officer | 4,563 0.0066% | $10.65 | $48,606 | -8.70% | |
| 2023-12-11 | Sale | Astle Christopher | SVP & Chief Financial Officer | 886 0.0013% | $9.13 | $8,089 | +5.63% | |
| 2023-06-16 | EcoR1 Capital, LLC | 10 percent owner | 3.35M 5.0195% | $8.12 | $27.2M | +7.27% | ||
| 2023-03-28 | EcoR1 Capital, LLC | 10 percent owner | 200,000 0.2981% | $8.00 | $1.6M | +6.44% | ||
| 2023-03-10 | Sale | Klompas Neil A | President & COO | 2,977 0.0044% | $7.83 | $23,298 | +6.56% | |
| 2023-01-20 | EcoR1 Capital, LLC | director | 163,400 0.2428% | $9.88 | $1.62M | -16.45% | ||
| 2023-01-19 | EcoR1 Capital, LLC | director | 144,100 0.2124% | $9.49 | $1.37M | -13.66% | ||
| 2023-01-18 | EcoR1 Capital, LLC | director | 203,000 0.3051% | $10.00 | $2.03M | -16.43% | ||
| 2023-01-17 | EcoR1 Capital, LLC | director | 440,000 0.6486% | $9.80 | $4.31M | -16.43% | ||
| 2023-01-13 | EcoR1 Capital, LLC | director | 342,100 0.5024% | $9.81 | $3.35M | -16.78% | ||
| 2023-01-11 | EcoR1 Capital, LLC | director | 106,300 0.1527% | $7.87 | $836,911 | +1.43% | ||
| 2023-01-10 | EcoR1 Capital, LLC | director | 920,000 1.3565% | $7.65 | $7.04M | +7.02% | ||
| 2022-11-10 | Sale | Josephson Neil | Chief Medical Officer | 2,475 0.0037% | $8.10 | $20,045 | -2.32% | |
| 2022-10-13 | Redmile Group, LLC | 10 percent owner | 30,481 0.0481% | $5.03 | $153,435 | +63.80% | ||
| 2022-03-10 | Sale | Klompas Neil A | Chief Operating Officer | 2,979 0.0048% | $6.88 | $20,496 | -6.14% |
Insider Historical Profitability
| Galbraith Kenneth | Chair & CEO | 23762 0.0339% | $8.40 | 0 | 2 | |
| Moore Paul Andrew | Chief Scientific Officer | 7367 0.0105% | $8.40 | 0 | 2 | |
| Astle Christopher | SVP & Chief Financial Officer | 6503 0.0093% | $8.40 | 0 | 3 | |
| EcoR1 Capital, LLC | 10 percent owner | 13437473 19.1958% | $8.40 | 9 | 0 | <0.0001% |
| Redmile Group, LLC | 10 percent owner | 6075918 8.6796% | $8.40 | 1 | 0 | +63.8% |
| LILLY ELI & CO | 10 percent owner | 2898647 4.1408% | $8.40 | 0 | 17 | |
| Tehrani Ali | Chief Executive Officer | 260325 0.3719% | $8.40 | 1 | 6 | +12.44% |
| Polverino Anthony J. | Chief Scientific Officer | 30979 0.0443% | $8.40 | 0 | 1 | |
| Klompas Neil A | President & COO | 17032 0.0243% | $8.40 | 0 | 5 | |
| Josephson Neil | Chief Medical Officer | 14449 0.0206% | $8.40 | 1 | 1 | <0.0001% |
| Cox Troy | director | 7500 0.0107% | $8.40 | 1 | 0 | <0.0001% |
| HAUSMAN DIANA | Chief Medical Officer | 5377 0.0077% | $8.40 | 0 | 5 | |
| O'Driscoll Kathryn | Chief People Officer | 5003 0.0071% | $8.40 | 0 | 2 | |
| Priour James | Chief Commercial Officer | 2003 0.0029% | $8.40 | 0 | 1 | |
| Poon David Kai Yuen | See Remarks | 0 0% | $8.40 | 0 | 1 |
Institutional Investor Ownership
| Ecor1 Capital Llc | $141.36M | 19.01 | 13.44M | 0% | +$0 | 3.59 | |
| Bvf Inc Il | $61.75M | 8.3 | 5.87M | 0% | +$0 | 0.45 | |
| Redmile Group | $58.5M | 7.87 | 5.56M | -3.96% | -$2.41M | 2.17 | |
| Morgan Stanley | $53.77M | 7.23 | 5.11M | +5.14% | +$2.63M | <0.01 | |
| BlackRock | $43.09M | 5.79 | 4.1M | +4.39% | +$1.81M | <0.01 | |
| Helm Capital Management LLC | $36.56M | 4.92 | 3.48M | 0% | +$0 | 1.08 | |
| The Vanguard Group | $25.86M | 3.48 | 2.46M | +2.65% | +$666,894.40 | <0.0001 | |
| Credit Suisse | $19.94M | 2.68 | 1.9M | -17.7% | -$4.29M | 0.02 | |
| Farallon Capital | $16.84M | 2.26 | 1.6M | -8.83% | -$1.63M | 0.12 | |
| Samsara Biocapital Llc | $15.35M | 2.06 | 1.46M | 0% | +$0 | 2.39 | |
| Acadian Asset Management | $13.72M | 1.85 | 1.31M | +4.07% | +$536,695.38 | 0.05 | |
| Tang Capital Management, LLC | $11.57M | 1.56 | 1.1M | 0% | +$0 | 0.05 | |
| Perceptive Advisors | $11.31M | 1.52 | 1.07M | 0% | +$0 | 0.01 | |
| Citadel Advisors LLC | $11.2M | 1.51 | 1.06M | +513.57% | +$9.38M | 0.01 | |
| State Street | $11.03M | 1.48 | 1.05M | +4.06% | +$430,478.41 | <0.0001 | |
| Deutsche Bank | $9.35M | 1.26 | 889,250 | +0.07% | +$6,469.80 | <0.01 | |
| Jacobs Levy Equity Management | $7.54M | 1.01 | 716,482 | +94.67% | +$3.67M | 0.03 | |
| Bridgeway Capital Management | $7.39M | 0.99 | 702,683 | +3.29% | +$235,300.83 | 0.14 | |
| Geode Capital Management | $7.04M | 0.95 | 668,984 | +4.58% | +$308,362.21 | <0.01 | |
| Granahan Investment Management | $6.91M | 0.93 | 656,607 | -6.27% | -$462,364.54 | 0.24 | |
| Healthcare Of Ontario Pension Plan Trust Fund | $6.3M | 0.85 | 599,000 | New | +$6.3M | 0.02 | |
| Arrowstreet Capital, Limited Partnership | $6.12M | 0.82 | 581,558 | +58.45% | +$2.26M | 0.01 | |
| AQR Capital | $5.15M | 0.69 | 489,502 | -28.66% | -$2.07M | 0.01 | |
| Jupiter Fund Management | $4.49M | 0.6 | 426,944 | -13.85% | -$722,071.62 | 0.01 | |
| PLATINUM INVESTMENT MANAGEMENT LTD | $4.4M | 0.59 | 418,376 | +2.08% | +$89,809.25 | 0.06 | |
| Northern Trust | $4.4M | 0.59 | 418,248 | +0.26% | +$11,593.04 | <0.01 | |
| Prosight Management Lp | $4.32M | 0.58 | 410,948 | New | +$4.32M | 1.2 | |
| Silvercrest Asset Management Group Inc | $4.13M | 0.56 | 393,021 | +4.57% | +$180,659.96 | 0.03 | |
| Dimensional Fund Advisors | $3.31M | 0.45 | 314,564 | -8.08% | -$290,888.58 | <0.01 | |
| Empowered Funds Llc | $3.11M | 0.42 | 295,783 | +8.18% | +$235,300.83 | 0.06 | |
| BNY Mellon | $3.1M | 0.42 | 294,878 | +6.49% | +$189,138.98 | <0.01 | |
| Monaco Asset Management Sam | $3.08M | 0.41 | 292,500 | -16.43% | -$604,900.00 | 1.42 | |
| Wellington Management Company | $3.01M | 0.41 | 286,595 | +39.63% | +$855,791.37 | <0.01 | |
| Picton Mahoney Asset Management | $2.99M | 0.4 | 284,378 | -20.32% | -$763,082.15 | 0.14 | |
| Goldman Sachs | $2.85M | 0.38 | 270,546 | +34.85% | +$735,611.02 | <0.01 | |
| O Shaughnessy Asset Management Llc | $2.69M | 0.36 | 255,497 | +51.45% | +$913,104.29 | 0.03 | |
| Wells Fargo | $2.51M | 0.34 | 238,687 | +0.18% | +$4,639.32 | <0.01 | |
| Invesco | $2.43M | 0.33 | 231,181 | +304.92% | +$1.83M | <0.01 | |
| Tejara Capital Ltd | $2.21M | 0.3 | 210,212 | -17.75% | -$477,218.71 | 0.75 | |
| Nuveen | $2.14M | 0.29 | 203,516 | +4.38% | +$89,777.67 | <0.01 | |
| Federated Hermes | $1.9M | 0.26 | 180,547 | +45,263.57% | +$1.9M | <0.01 | |
| Assenagon Asset Management S.A. | $1.75M | 0.24 | 166,549 | New | +$1.75M | 0.01 | |
| Qube Research & Technologies | $1.69M | 0.23 | 160,299 | +143.21% | +$992,972.00 | <0.01 | |
| Kennedy Capital Management Inc | $1.62M | 0.22 | 154,362 | -1.07% | -$17,589.44 | 0.03 | |
| Allspring Global Investments | $1.51M | 0.2 | 143,215 | -37.08% | -$887,993.32 | <0.01 | |
| Ameriprise Financial | $1.49M | 0.2 | 141,793 | +15.35% | +$198,480.92 | <0.0001 | |
| Charles Schwab | $1.32M | 0.18 | 125,491 | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $1.22M | 0.16 | 115,600 | +686.39% | +$1.06M | <0.01 | |
| Franklin Templeton Investments | $1.2M | 0.16 | 114,458 | +159.06% | +$739,303.42 | <0.0001 | |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $1.04M | 0.14 | 99,064 | +15.35% | +$138,716.68 | <0.01 |